Skip to content

Iron supplementation in pregnancy

Evaluation of the effect of Iron supplement use on pregnancy outcomes in women without iron deficiency referred to Hazrat zeynab and Hafez gynecology clinic in 2016

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2017051533976N1
Enrollment
90
Registered
2017-06-03
Start date
2017-03-20
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Iron deficiency anemia in pregnancy. Other iron deficiency anaemias

Interventions

Intervention 1: Group A: Pregnant women who fit their iron stores (serum ferritin level <30 ppm) and typically take 60 mg/day ferrous sulfate. Intervention 2: The second group of pregnant women with t
Treatment - Drugs
Group A: Pregnant women who fit their iron stores (serum ferritin level <30 ppm) and typically take 60 mg/day ferrous sulfate.
The second group of pregnant women with thalassemia minor levels of serum ferritin them more than 30 micrograms per liter is needed to get pills of iron supplements are pregnant women that the serum f
The third group of pregnant women that their ferritin level of less than 30 micrograms per deciliter of iron deficiency and 60 mg/day iron supplements they consume.

Sponsors

Vice chancellor for research of Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age between 18 to 40 years without any underlying condition such as diabetes, hypertension, liver disease and kidney disease, heart disease and vascular, no history of pregnancy complications included preeclampsia, gestational diabetes, premature labor, miscarriage, stillbirth and low birth weight in previous pregnancies, no risk factors for pre-eclampsia, gestational diabetes and IUGR. Exclusion criteria: younger than 18 and older than 40 years, having a risk factor for preeclampsia, gestational diabetes and IUGR, diabetes, obesity, multiple pregnancy, cardiovascular disease, kidney disease, connective tissue disease and history of preeclampsia in a previous pregnancy, having a history of pregnancy complications in previous pregnancies.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Hemoglobin level. Timepoint: At first, seconed and third trimister pregnancy. Method of measurement: Laboratory.;Serum ferritin level. Timepoint: At first, seconed and third trimister pregnancy. Method of measurement: Laboratory.;MCV level. Timepoint: At first, seconed and third trimister pregnancy. Method of measurement: Laboratory.;MCH level. Timepoint: At first, seconed and third trimister pregnancy. Method of measurement: Laboratory.;Serum iron level. Timepoint: At first, seconed and third trimister pregnancy. Method of measurement: Laboratory.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Leilyia Abassi

Shiraz University of Medical Sciences

hafez_perina@sums.ac.ir+98 71 3233 2365

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026